MARA Holdings
MARA
MicroStrategy
MSTR
Tesla
TSLA
Coinbase
COIN
Amazon
AMZN
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 2.130
- 0.0000.00%
Close Jan 3 16:00 ET
- 2.130
- 0.0000.00%
Post 20:01 ET
40.16MMarket Cap-2.27P/E (TTM)
2.200High2.080Low122.18KVolume2.200Open2.130Pre Close263.14KTurnover1.03%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High2.46P/B25.17MFloat Cap0.46052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM5.63%Amplitude0.420Historical Low2.153Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Chemomab Therapeutics Stock Forum
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024.
The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 w...
1 min ago
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024
Resale of up to 8.1 Mln Adss
No comment yet